N-ethyl-4-ethoxycarbonylmethylaniline | 39718-92-8

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N-ethyl-4-ethoxycarbonylmethylaniline
• 英文别名: Ethyl 2-(4-(ethylamino)phenyl)acetate；ethyl 2-[4-(ethylamino)phenyl]acetate
• CAS: 39718-92-8
• 化学式: C₁₂H₁₇NO₂
• 分子量: 207.272
• InChiKey: OXLHUYOHAIHLSF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  15
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-ethyl-4-ethoxycarbonylmethylaniline 、 2-(溴甲基)苯甲酸乙酯 在 碳酸氢钠 作用下， 以 水 为溶剂， 生成 N-ethyl-N-(2-ethoxycarbonylbenzyl)-4-ethoxycarbonylmethylaniline
  参考文献：
  名称：

  11-Oxodibenz(b,e)azepines

  摘要：

  通式##STR1##的化合物或其盐、酯或酰胺衍生物；以及它们的制备方法。在这个式子中，R.sub.O代表氢或较低的烷基，R.sub.2代表氢、卤素或硝基，R.sub.3代表氢或卤素，R.sub.4代表氢或较低的烷基；当R.sub.O是氢时，R.sub.2、R.sub.3和R.sub.4都是氢，而群##STR2##存在于2位。这些化合物表现出优越的止痛和/或抗炎作用，几乎没有胃肠道问题。

  公开号：

  US04230703A1
• 作为产物：
  描述：

  4-氨基苯乙酸乙酯 、 碘乙烷 在 N,N-二异丙基乙胺 作用下， 以 甲苯 为溶剂， 反应 18.0h， 生成 N-ethyl-4-ethoxycarbonylmethylaniline
  参考文献：
  名称：

  2-[N-Alkyl(R-phenyl)-aminomethyl]-3-phenyl-7-trifluoromethylquinoxalines as anticancer agents inhibitors of folate enzymes

  摘要：

  Based on our previous results on the ascertained potent growth inhibition effect against a panel of 60 human tumors cell lines at National Cancer Institute of Bethesda (NCI), we have synthesized a novel series of thirty-one 2-[N-methyl(R-phenyl)-aminomethyl]-3-phenyl-7-trifluoromethylquinoxalines (1-31). The lead compound 1 was previously reported to be endowed with significant inhibition against hDHFR enzyme, with a Xi of 0.2 mu M. Docking studies were performed on compound 1 and here reported to predict its binding conformation to human dihydrofolate reductase (hDHFR). All compounds (1-31) were assayed versus hDHFR and human thymidylate synthase (hTS). From the screening emerged that all compounds inhibited hDHFR with Xi values included between 0.2 and 11 mu M, while only a few (6, 21, 24, 27, 29) showed great activity and selectivity towards hTS. Evaluation of the anticancer activity was performed by NCI, first against the three cell line panel, and only the most active compounds (17, 21, 24, 26, 27) were evaluated on a panel of 60 human tumor cell lines. Compound 21 was the most active against all cell lines with log GI50 equal to -5.49 and log LC50 equal to -4.19 and maintained significant percent of growth inhibition on seven cancer cell lines at the concentration of 1 mu M. Compound 17 was the second most active and moreover showed interesting selectivity against some cell lines (Lung cancer: A549/ATCC, Melanoma: UACC-257, Ovarian Cancer: ovcar-8 and Renal cancer: RXF 393) at all concentration examined (100-0.01 mu M). (C) 2014 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2014.01.048

文献信息

• Phenylacetic acid derivatives
  申请人：——

  公开号：US03957850A1

  公开（公告）日：1976-05-18

  The present invention relates to phenylacetic acid derivatives having the general formula: ##SPC1## In which R.sub.1 represents a lower alkyl radical, a lower alkenyl radical, a lower alkynyl radical or an aryl(lower) alkyl radical, R.sub.2 represents hydrogen or a methyl radical, their esters and their salts with bases and acids. Said derivatives have in particular an analgesic and/or anti-inflammatory activity.

  本发明涉及具有一般式的苯乙酸衍生物：##SPC1## 其中R1代表低烷基基团、低烯基基团、低炔基基团或芳基（低）烷基基团，R2代表氢或甲基基团，它们的酯和与酸碱的盐。所述衍生物具有特别的镇痛和/或抗炎活性。
• HETEROCYCLIC DERIVATIVE HAVING INHIBITORY ACTIVITY ON TYPE-I 11 DATA-HYDROXYSTEROID DEHYDROGENASE
  申请人：Itai Akiko

  公开号：US20100234363A1

  公开（公告）日：2010-09-16

  Disclosed is a compound which is useful as an 11β-hydroxysteroid dehydrogenase type 1 inhibitor. A compound represented by the formula: its pharmaceutically acceptable salt, or a solvate thereof, wherein X is O or S, a broken line and a wavy line represent the presence or the absence of a bond, (i) when a broken line represents the presence of a bond, a wavy line represents the absence of a bond, R 2 and R 3 are each independently hydrogen, halogen, cyano, hydroxy, carboxy, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl or the like, (ii) when a broken line represents the absence of a bond, a wavy line represents the presence of a bond, R 1 and R 4 are each independently hydrogen, halogen or the like, R 2 and R 3 are each independently hydrogen, halogen, cyano, hydroxy, carboxy, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl or the like, and R 5 and R 6 are each independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl or the like.

  本发明涉及一种化合物，可用作11β-羟基类固醇脱氢酶1型抑制剂。化合物的表示式如下：其药学上可接受的盐或其溶剂化物，其中X为O或S，一条断线和一条波浪线分别表示键的存在或不存在，(i) 当断线表示键的存在时，波浪线表示键的不存在，R2和R3各自独立地表示氢、卤素、氰基、羟基、羧基、可选取代的烷基、可选取代的烯基、可选取代的炔基或类似物，(ii) 当断线表示键的不存在时，波浪线表示键的存在，R1和R4各自独立地表示氢、卤素或类似物，R2和R3各自独立地表示氢、卤素、氰基、羟基、羧基、可选取代的烷基、可选取代的烯基、可选取代的炔基或类似物，而R5和R6各自独立地表示氢、可选取代的烷基、可选取代的烯基、可选取代的炔基或类似物。
• US3957850A
  申请人：——

  公开号：US3957850A

  公开（公告）日：1976-05-18
• US4230703A
  申请人：——

  公开号：US4230703A

  公开（公告）日：1980-10-28
• 2-[N-Alkyl(R-phenyl)-aminomethyl]-3-phenyl-7-trifluoromethylquinoxalines as anticancer agents inhibitors of folate enzymes
  作者：Sandra Piras、Antonio Carta、Irene Briguglio、Paola Corona、Giuseppe Paglietti、Rosaria Luciani、Maria Paola Costi、Stefania Ferrari

  DOI：10.1016/j.ejmech.2014.01.048

  日期：2014.3

  Based on our previous results on the ascertained potent growth inhibition effect against a panel of 60 human tumors cell lines at National Cancer Institute of Bethesda (NCI), we have synthesized a novel series of thirty-one 2-[N-methyl(R-phenyl)-aminomethyl]-3-phenyl-7-trifluoromethylquinoxalines (1-31). The lead compound 1 was previously reported to be endowed with significant inhibition against hDHFR enzyme, with a Xi of 0.2 mu M. Docking studies were performed on compound 1 and here reported to predict its binding conformation to human dihydrofolate reductase (hDHFR). All compounds (1-31) were assayed versus hDHFR and human thymidylate synthase (hTS). From the screening emerged that all compounds inhibited hDHFR with Xi values included between 0.2 and 11 mu M, while only a few (6, 21, 24, 27, 29) showed great activity and selectivity towards hTS. Evaluation of the anticancer activity was performed by NCI, first against the three cell line panel, and only the most active compounds (17, 21, 24, 26, 27) were evaluated on a panel of 60 human tumor cell lines. Compound 21 was the most active against all cell lines with log GI50 equal to -5.49 and log LC50 equal to -4.19 and maintained significant percent of growth inhibition on seven cancer cell lines at the concentration of 1 mu M. Compound 17 was the second most active and moreover showed interesting selectivity against some cell lines (Lung cancer: A549/ATCC, Melanoma: UACC-257, Ovarian Cancer: ovcar-8 and Renal cancer: RXF 393) at all concentration examined (100-0.01 mu M). (C) 2014 Elsevier Masson SAS. All rights reserved.